Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement

Michael P. Flaherty; Amr Mohsen; Joseph B. Moore; Carlo R. Bartoli; Erik Schneibel; Wasiq Rawasia; Matthew L. Williams; Kendra J. Grubb; Glenn A. Hirsch

doi:10.1002/ccd.25668

Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement

Michael P. Flaherty, Amr Mohsen, Joseph B. Moore, Carlo R. Bartoli, Erik Schneibel, Wasiq Rawasia, Matthew L. Williams, Kendra J. Grubb, Glenn A. Hirsch

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Background: Data are limited regarding transcatheter aortic valve replacement (TAVR)-related thrombocytopenia (TP). We sought to thoroughly characterize the presence, clinical impact, and severity of TP associated with TAVR. Methods and Results: Data were collected from 90 patients who underwent TAVR using the Edwards SAPIEN valve (59 TF, 29 TA, 2 Tao). Platelet counts were evaluated peri-procedurally and for 8 days following TAVR. Platelet levels were compared and patients were divided into a no TP (No-TP) group 1, acquired (new) TP (NTP) group 2, pre-existing (pre-TAVR) TP (PTP) group 3, and further stratified based on the severity of TP: mild (M) TP (100-149 × 10³cell/μL) and moderate-severe (MS) TP (

Original language	English (US)
Pages (from-to)	118-129
Number of pages	12
Journal	Catheterization and Cardiovascular Interventions
Volume	85
Issue number	1
DOIs	https://doi.org/10.1002/ccd.25668
State	Published - Jan 1 2015
Externally published	Yes

Keywords

Predictors
TAVR
Thrombocytopenia

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Radiology Nuclear Medicine and imaging
General Medicine

Access to Document

10.1002/ccd.25668

Cite this

@article{950d2d4925574bd1999492bfc53d29ae,

title = "Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement",

abstract = "Background: Data are limited regarding transcatheter aortic valve replacement (TAVR)-related thrombocytopenia (TP). We sought to thoroughly characterize the presence, clinical impact, and severity of TP associated with TAVR. Methods and Results: Data were collected from 90 patients who underwent TAVR using the Edwards SAPIEN valve (59 TF, 29 TA, 2 Tao). Platelet counts were evaluated peri-procedurally and for 8 days following TAVR. Platelet levels were compared and patients were divided into a no TP (No-TP) group 1, acquired (new) TP (NTP) group 2, pre-existing (pre-TAVR) TP (PTP) group 3, and further stratified based on the severity of TP: mild (M) TP (100-149 × 103cell/μL) and moderate-severe (MS) TP (",

keywords = "Predictors, TAVR, Thrombocytopenia",

author = "Flaherty, {Michael P.} and Amr Mohsen and Moore, {Joseph B.} and Bartoli, {Carlo R.} and Erik Schneibel and Wasiq Rawasia and Williams, {Matthew L.} and Grubb, {Kendra J.} and Hirsch, {Glenn A.}",

year = "2015",

month = jan,

day = "1",

doi = "10.1002/ccd.25668",

language = "English (US)",

volume = "85",

pages = "118--129",

journal = "Catheterization and Cardiovascular Interventions",

issn = "1522-1946",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement

AU - Flaherty, Michael P.

AU - Mohsen, Amr

AU - Moore, Joseph B.

AU - Bartoli, Carlo R.

AU - Schneibel, Erik

AU - Rawasia, Wasiq

AU - Williams, Matthew L.

AU - Grubb, Kendra J.

AU - Hirsch, Glenn A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Data are limited regarding transcatheter aortic valve replacement (TAVR)-related thrombocytopenia (TP). We sought to thoroughly characterize the presence, clinical impact, and severity of TP associated with TAVR. Methods and Results: Data were collected from 90 patients who underwent TAVR using the Edwards SAPIEN valve (59 TF, 29 TA, 2 Tao). Platelet counts were evaluated peri-procedurally and for 8 days following TAVR. Platelet levels were compared and patients were divided into a no TP (No-TP) group 1, acquired (new) TP (NTP) group 2, pre-existing (pre-TAVR) TP (PTP) group 3, and further stratified based on the severity of TP: mild (M) TP (100-149 × 103cell/μL) and moderate-severe (MS) TP (

AB - Background: Data are limited regarding transcatheter aortic valve replacement (TAVR)-related thrombocytopenia (TP). We sought to thoroughly characterize the presence, clinical impact, and severity of TP associated with TAVR. Methods and Results: Data were collected from 90 patients who underwent TAVR using the Edwards SAPIEN valve (59 TF, 29 TA, 2 Tao). Platelet counts were evaluated peri-procedurally and for 8 days following TAVR. Platelet levels were compared and patients were divided into a no TP (No-TP) group 1, acquired (new) TP (NTP) group 2, pre-existing (pre-TAVR) TP (PTP) group 3, and further stratified based on the severity of TP: mild (M) TP (100-149 × 103cell/μL) and moderate-severe (MS) TP (

KW - Predictors

KW - TAVR

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84923248670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923248670&partnerID=8YFLogxK

U2 - 10.1002/ccd.25668

DO - 10.1002/ccd.25668

M3 - Article

C2 - 25204308

AN - SCOPUS:84923248670

SN - 1522-1946

VL - 85

SP - 118

EP - 129

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

IS - 1

ER -

Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this